DOCSLIB.ORG

Integrated Review

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Integrated Review CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 214103Orig1s000 INTEGRATED REVIEW NDA 214103 Oxlumo (lumasiran) Integrated Review Table 1. Administrative Application Information Category Application Information Application type NDA Application number(s) 214103 Priority or standard Priority Submit date(s) 4/3/2020 Received date(s) 4/3/2020 PDUFA goal date 12/3/2020 Division/office Division of Cardiology and Nephrology (DCN) Review completion date 11/18/2020 Established/proper name Lumasiran (Proposed) proprietary name Oxlumo Pharmacologic class Small interfering RNA Code name AD-65585, ALN-65585, ALN-GO1 Applicant Alnylam Pharmaceuticals Dosage form(s)/formulation(s) Injectable 94.5 mg/0.5 mL single-dose vial Dosing regimen Subcutaneous injection based on body weight. Applicant proposed Treatment of primary hyperoxaluria type 1 (PH1) in pediatric and indication(s)/ population(s) adult patients. Proposed SNOMED indication 65520001 Primary hyperoxaluria, type 1 (disorder) Regulatory action Approval Approved dosage Body Weight <10 kg: 6 mg/kg monthly for 3 doses then 3 mg/kg monthly; 10 kg to <20 kg: 6 mg/kg monthly for 3 doses then 6 mg/kg every 3 months; 20 kg: 3 mg/kg monthly for 3 doses then 3 mg/kg every 3 months Approved indication For the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients Approved SNOMED term for 65520001 Primary hyperoxaluria, type 1 (disorder) indication i Integrated Review Template, version 2.0 (04/23/2020) Reference ID: 4704669 NDA 214103 Oxlumo (lumasiran) Table of Contents Table of Tables ............................................................................................................ vi Table of Figures ........................................................................................................... ix Glossary......................................................................................................................1 I. Executive Summary....................................................................................................3 1. Summary of Regulatory Action .............................................................................3 2. Benefit-Risk Assessment........................................................................................6 2.1. Benefit-Risk Framework .................................................................................6 2.2. Conclusions Regarding Benefit-Risk ..............................................................8 II. Interdisciplinary Assessment.....................................................................................9 3. Introduction ............................................................................................................9 3.1. Review Issue List...........................................................................................10 3.2. Approach to the Review ................................................................................10 4. Patient Experience Data .......................................................................................12 5. Pharmacologic Activity, Pharmacokinetics, and Clinical Pharmacology............13 5.1. Nonclinical Assessment of Potential Effectiveness.......................................17 6. Assessment of Effectiveness ................................................................................18 6.1. Dose and Dose Responsiveness.....................................................................18 6.2. Clinical Trials Intended to Demonstrate Efficacy .........................................22 6.2.1. Results of Analyses, ILLUMINATE-A and -B ......................................22 6.2.2. Trial ALN-GO1-003 (ILLUMINATE-A)...............................................22 6.2.2.1. Design, ILLUMINATE-A................................................................22 6.2.2.2. Eligibility Criteria, ILLUMINATE-A..............................................25 6.2.2.3. Statistical Analysis Plan, ILLUMINATE-A ....................................25 6.2.2.4. Results of Analyses, ILLUMINATE-A ...........................................26 6.2.3. ALN-GO1-004 (ILLUMINATE-B)........................................................36 6.2.3.1. Design, ILLUMINATE-B ................................................................37 6.2.3.2. Eligibility Criteria, ILLUMINATE-B..............................................38 6.2.3.3. Statistical Analysis Plan, ILLUMINATE-B.....................................38 6.2.3.4. Results of Analyses, ILLUMINATE B ............................................39 6.3. Key Review Issues Relevant to Evaluation of Benefit..................................42 7. Risk and Risk Management..................................................................................42 ii Integrated Review Template, version 2.0 (04/23/2020) Reference ID: 4704669 NDA 214103 Oxlumo (lumasiran) 7.1. Potential Risks or Safety Concerns Based on Nonclinical Data....................42 7.2. Potential Risks or Safety Concerns Based on Drug Class or Other Drug- Specific Factors ..............................................................................................46 7.3. Potential Safety Concerns Identified Through Postmarket Experience ........47 7.4. FDA Approach to the Safety Review ............................................................47 7.5. Adequacy of Clinical Safety Database ..........................................................47 7.6. Safety Findings and Concerns Based on Review of Clinical Safety Database..........................................................................................................48 7.6.1. Safety Findings and Concerns, ILLUMINATE-A and -B......................48 7.6.2. Safety Findings and Concerns, ILLUMINATE-A..................................49 7.6.2.1. Overall Treatment-Emergent Adverse Event Summary, ILLUMINATE-A ....................................................................................49 7.6.2.2. Deaths, ILLUMINATE-A ................................................................49 7.6.2.3. Serious Adverse Events, ILLUMINATE-A.....................................49 7.6.2.4. Dropouts and/or Discontinuations Due to Adverse Events, ILLUMINATE-A ....................................................................................50 7.6.2.5. Treatment-Emergent Adverse Events, ILLUMINATE-A................50 7.6.2.6. Laboratory Findings, ILLUMINATE-A ..........................................53 7.6.3. Safety Findings and Concerns, ILLUMINATE-B..................................54 7.6.3.1. Overall Treatment-Emergent Adverse Event Summary, ILLUMINATE-B ....................................................................................54 7.6.3.2. Deaths, ILLUMINATE-B ................................................................54 7.6.3.3. Serious Adverse Events, ILLUMINATE-B .....................................55 7.6.3.4. Dropouts and/or Discontinuations Due to Adverse Events, ILLUMINATE-B ....................................................................................55 7.6.3.5. Treatment-Emergent Adverse Events, ILLUMINATE-B................55 7.6.3.6. Laboratory Findings, ILLUMINATE-B...........................................56 7.7. Key Review Issues Relevant to Evaluation of Risk ......................................57 8. Therapeutic Individualization ..............................................................................57 8.1. Intrinsic Factors .............................................................................................57 8.2. Drug Interactions ...........................................................................................60 8.3. Plans for Pediatric Drug Development ..........................................................60 8.4. Pregnancy and Lactation................................................................................60 9. Product Quality ....................................................................................................62 iii Integrated Review Template, version 2.0 (04/23/2020) Reference ID: 4704669 NDA 214103 Oxlumo (lumasiran) 9.1. Device or Combination Product Considerations ...........................................62 10. Human Subjects Protections/Clinical Site and Other Good Clinical Practice Inspections/Financial Disclosure........................................................................62 11. Advisory Committee Summary..........................................................................64 III. Appendices.............................................................................................................64 12. Summary of Regulatory History ........................................................................64 13. Pharmacology Toxicology: Additional Information and Assessment ...............65 13.1. Summary Review of Studies Submitted Under the IND.............................65 13.1.1. Primary Pharmacology..........................................................................65 13.1.2. Secondary Pharmacology......................................................................66 13.1.3. Toxicology ............................................................................................70 13.1.3.1. General Toxicology (Pivotal).........................................................70 13.1.3.2. Reproductive Toxicology ...............................................................77 13.1.3.3. Impurities/Degradants ....................................................................81 13.2.
Load more

Recommended publications
  • Clinical Applications and Implications of Common and Founder Mutations in Indian Subpopulations
    REVIEW OFFICIAL JOURNAL Clinical Applications and Implications of Common and Founder Mutations in Indian Subpopulations www.hgvs.org Arunkanth Ankala,1∗ † Parag M. Tamhankar,2 † C. Alexander Valencia,3,4 Krishna K. Rayam,5 Manisha M. Kumar,5 and Madhuri R. Hegde1 1Department of Human Genetics, Emory University School of Medicine, Atlanta, Georgia; 2ICMR Genetic Research Center, National Institute for Research in Reproductive Health, Mumbai, Maharashtra, India; 3Division of Human Genetics, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio; 4Department of Pediatrics, University of Cincinnati Medical School, Cincinnati, Ohio; 5Department of Biosciences, CMR Institute of Management Studies, Bangalore, Karnataka, India Communicated by Arupa Ganguly Received 24 October 2013; accepted revised manuscript 16 September 2014. Published online 27 November 2014 in Wiley Online Library (www.wiley.com/humanmutation). DOI: 10.1002/humu.22704 that include a lack of widespread awareness about genetic disorders in the general population and the scarcity of specialized medical ABSTRACT: South Asian Indians represent a sixth of the world’s population and are a racially, geographically, and professionals and affordable genetic tests. Seeking a molecular di- genetically diverse people. Their unique anthropological agnosis and understanding the risk estimates are critical to making structure, prevailing caste system, and ancient religious sound reproductive choices, especially in families with an affected practices have all impacted the genetic composition of most individual. Adding to this adversity is the absence of a properly func- of the current-day Indian population. With the evolving tioning social health care system and insufficient encouragement socio-religious and economic activities of the subsects and of individual health insurance by the government.
    [Show full text]
  • DRUGS REQUIRING PRIOR AUTHORIZATION in the MEDICAL BENEFIT Page 1
    Effective Date: 08/01/2021 DRUGS REQUIRING PRIOR AUTHORIZATION IN THE MEDICAL BENEFIT Page 1 Therapeutic Category Drug Class Trade Name Generic Name HCPCS Procedure Code HCPCS Procedure Code Description Anti-infectives Antiretrovirals, HIV CABENUVA cabotegravir-rilpivirine C9077 Injection, cabotegravir and rilpivirine, 2mg/3mg Antithrombotic Agents von Willebrand Factor-Directed Antibody CABLIVI caplacizumab-yhdp C9047 Injection, caplacizumab-yhdp, 1 mg Cardiology Antilipemic EVKEEZA evinacumab-dgnb C9079 Injection, evinacumab-dgnb, 5 mg Cardiology Hemostatic Agent BERINERT c1 esterase J0597 Injection, C1 esterase inhibitor (human), Berinert, 10 units Cardiology Hemostatic Agent CINRYZE c1 esterase J0598 Injection, C1 esterase inhibitor (human), Cinryze, 10 units Cardiology Hemostatic Agent FIRAZYR icatibant J1744 Injection, icatibant, 1 mg Cardiology Hemostatic Agent HAEGARDA c1 esterase J0599 Injection, C1 esterase inhibitor (human), (Haegarda), 10 units Cardiology Hemostatic Agent ICATIBANT (generic) icatibant J1744 Injection, icatibant, 1 mg Cardiology Hemostatic Agent KALBITOR ecallantide J1290 Injection, ecallantide, 1 mg Cardiology Hemostatic Agent RUCONEST c1 esterase J0596 Injection, C1 esterase inhibitor (recombinant), Ruconest, 10 units Injection, lanadelumab-flyo, 1 mg (code may be used for Medicare when drug administered under Cardiology Hemostatic Agent TAKHZYRO lanadelumab-flyo J0593 direct supervision of a physician, not for use when drug is self-administered) Cardiology Pulmonary Arterial Hypertension EPOPROSTENOL (generic)
    [Show full text]
  • Oregon Medicaid Pharmaceutical Services Prior Authorization Criteria
    Oregon Medicaid Pharmaceutical Services Prior Authorization Criteria HEALTH SYSTEMS DIVISION Prior authorization (PA) criteria for fee-for-service prescriptions for Oregon Health Plan clients March 1, 2021 Contents Contents ................................................................................................................................................................ 2 Introduction........................................................................................................................................................... 7 About this guide ......................................................................................................................................... 7 How to use this guide ................................................................................................................................. 7 Administrative rules and supplemental information .................................................................................. 7 Update information............................................................................................................................................... 8 Effective March 1, 2021 ............................................................................................................................ 8 Substantive updates and new criteria ............................................................................................. 8 Clerical changes ............................................................................................................................
    [Show full text]
  • Fructose As an Endogenous Toxin
    HEPATOCYTE MOLECULAR CYTOTOXIC MECHANISM STUDY OF FRUCTOSE AND ITS METABOLITES INVOLVED IN NONALCOHOLIC STEATOHEPATITIS AND HYPEROXALURIA By Yan (Cynthia) Feng A thesis submitted in the conformity with the requirements for the degree of Master of Science Graduate Department of Pharmaceutical Sciences University of Toronto © Copyright by Yan (Cynthia) Feng 2010 ABSTRACT HEPATOCYTE MOLECULAR CYTOTOXIC MECHANISM STUDY OF FRUCTOSE AND ITS METABOLITES INVOLVED IN NONALCOHOLIC STEATOHEPATITIS AND HYPEROXALURIA Yan (Cynthia) Feng Master of Science, 2010 Department of Pharmaceutical Sciences University of Toronto High chronic fructose consumption is linked to a nonalcoholic steatohepatitis (NASH) type of hepatotoxicity. Oxalate is the major endpoint of fructose metabolism, which accumulates in the kidney causing renal stone disease. Both diseases are life-threatening if not treated. Our objective was to study the molecular cytotoxicity mechanisms of fructose and some of its metabolites in the liver. Fructose metabolites were incubated with primary rat hepatocytes, but cytotoxicity only occurred if the hepatocytes were exposed to non-toxic amounts of hydrogen peroxide such as those released by activated immune cells. Glyoxal was most likely the endogenous toxin responsible for fructose induced toxicity formed via autoxidation of the fructose metabolite glycolaldehyde catalyzed by superoxide radicals, or oxidation by Fenton’s hydroxyl radicals. As for hyperoxaluria, glyoxylate was more cytotoxic than oxalate presumably because of the formation of condensation product oxalomalate causing mitochondrial toxicity and oxidative stress. Oxalate toxicity likely involved pro-oxidant iron complex formation. ii ACKNOWLEDGEMENTS I would like to dedicate this thesis to my family. To my parents, thank you for the sacrifices you have made for me, thank you for always being there, loving me and supporting me throughout my life.
    [Show full text]
  • CDER Breakthrough Therapy Designation Approvals Data As of December 31, 2020 Total of 190 Approvals
    CDER Breakthrough Therapy Designation Approvals Data as of December 31, 2020 Total of 190 Approvals Submission Application Type and Proprietary Approval Use Number Number Name Established Name Applicant Date Treatment of patients with previously BLA 125486 ORIGINAL-1 GAZYVA OBINUTUZUMAB GENENTECH INC 01-Nov-2013 untreated chronic lymphocytic leukemia in combination with chlorambucil Treatment of patients with mantle cell NDA 205552 ORIGINAL-1 IMBRUVICA IBRUTINIB PHARMACYCLICS LLC 13-Nov-2013 lymphoma (MCL) Treatment of chronic hepatitis C NDA 204671 ORIGINAL-1 SOVALDI SOFOSBUVIR GILEAD SCIENCES INC 06-Dec-2013 infection Treatment of cystic fibrosis patients age VERTEX PHARMACEUTICALS NDA 203188 SUPPLEMENT-4 KALYDECO IVACAFTOR 21-Feb-2014 6 years and older who have mutations INC in the CFTR gene Treatment of previously untreated NOVARTIS patients with chronic lymphocytic BLA 125326 SUPPLEMENT-60 ARZERRA OFATUMUMAB PHARMACEUTICALS 17-Apr-2014 leukemia (CLL) for whom fludarabine- CORPORATION based therapy is considered inappropriate Treatment of patients with anaplastic NOVARTIS lymphoma kinase (ALK)-positive NDA 205755 ORIGINAL-1 ZYKADIA CERITINIB 29-Apr-2014 PHARMACEUTICALS CORP metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib Treatment of relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients NDA 206545 ORIGINAL-1 ZYDELIG IDELALISIB GILEAD SCIENCES INC 23-Jul-2014 for whom rituximab alone would be considered appropriate therapy due to other co-morbidities
    [Show full text]
  • Antenatal Diagnosis of Inborn Errors Ofmetabolism
    816 ArchivesofDiseaseinChildhood 1991;66: 816-822 CURRENT PRACTICE Arch Dis Child: first published as 10.1136/adc.66.7_Spec_No.816 on 1 July 1991. Downloaded from Antenatal diagnosis of inborn errors of metabolism M A Cleary, J E Wraith The introduction of experimental treatment for Sample requirement and techniques used in lysosomal storage disorders and the increasing prenatal diagnosis understanding of the molecular defects behind By far the majority of antenatal diagnoses are many inborn errors have overshadowed the fact performed on samples obtained by either that for many affected families the best that can amniocentesis or chorion villus biopsy. For be offered is a rapid, accurate prenatal diag- some disorders, however, the defect is not nostic service. Many conditions remain at best detectable in this material and more invasive only partially treatable and as a consequence the methods have been applied to obtain a diagnos- majority of parents seek antenatal diagnosis in tic sample. subsequent pregnancies, particularly for those disorders resulting in a poor prognosis in terms of either life expectancy or normal neurological FETAL LIVER BIOPSY development. Fetal liver biopsy has been performed to The majority of inborn errors result from a diagnose ornithine carbamoyl transferase defi- specific enzyme deficiency, but in some the ciency and primary hyperoxaluria type 1. primary defect is in a transport system or Glucose-6-phosphatase deficiency (glycogen enzyme cofactor. In some conditions the storage disease type I) could also be detected by biochemical defect is limited to specific tissues this method. The technique, however, is inva- only and this serves to restrict the material avail- sive and can be performed by only a few highly able for antenatal diagnosis for these disorders.
    [Show full text]
  • Buckeye Health Plan Medicaid Criteria Updates – Q2 2020
    Effective date: 06/29/20 Buckeye Health Plan Medicaid Criteria Updates –Q2 2020 Buckeye Health Plan (BHP) routinely reviews their Prior Authorization (PA) and Medical Necessity (MN) criteria. Decisions on PA and MN criteria content are coordinated with input from pharmacy and medical practitioners, Buckeye Health Plan representatives, and review of current available medical literature and professional standards of practice. Below is the list of changes to the Medicaid criteria this quarter. For the most current program description you may call Provider Services at 1-866-296-8731 (TTY/TTD Policy/ Coverage Criteria Guideline Applicable Revision Summary Description Business Clinically Significant Change(s) CP.PHAR.16 Palivizumab (Synagis) Commercial, 2Q 2020 annual review: added appendix E: dose rounding guidelines; added reference to appendix E HIM, within criteria; revised HIM-Medical Benefit to HIM line of business; references reviewed and Medicaid updated. CP.PHAR.50 Binimetinib (Mektovi) Commercial, 2Q 2020 annual review: added NCCN compendium supported off-label use in colon and rectal HIM, cancers in combination with Braftovi and either Erbitux or Vectibix; references reviewed and Medicaid updated. CP.PHAR.60 Capecitabine (Xeloda) HIM, 2Q 2020 annual review: NCCN compendium-supported changes to occult primary and Medicaid neuroendocrine tumors of the pancreas indications as capecitabine use as a single agent is supported for both of these indications; added NCCN compendium-supported uses of small bowel adenocarcinomas and thymomas and thymic carcinomas; added requirement for medical justification if brand Xeloda requested as generic available; references reviewed and updated. CP.PHAR.65 Imatinib (Gleevec) Commercial, 2Q 2020 annual review: HIM nonformulary language removed; GVHD NCCN recommended use HIM, added; Continued Therapy authorization duration changed to 12 months for consistency with other Medicaid oral oncology agents; references reviewed and updated.
    [Show full text]
  • Health Plan Insights
    Health Plan Insights September 2020 Updates from August 2020 Confidential – Do not copy or distribute. 800-361-4542 | elixirsolutions.com 1 Recent FDA Approvals New Medications TRADE NAME DOSAGE FORM APPROVAL MANUFACTURER INDICATION(S) (generic name) STRENGTH DATE Blenrep GlaxoSmithKline Injection, For the treatment of adult patients with August 5, 2020 (belantamab 2.5 mg/kg relapsed or refractory multiple myeloma who mafodotin-blmf) have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. Lampit Bayer Healthcare Tablets, For use in pediatric patients (birth to less than August 6, 2020 (nifurtimox) 30 mg and 120 18 years of age and weighing at least 2.5 kg) mg for the treatment of Chagas disease (American Trypanosomiasis), caused by Trypanosoma cruzi. Olinvyk Trevena, Inc. Injection, For use in adults for the management of August 7, 2020 (oliceridine) 1 mg/mL acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. Evrysdi Genentech, Inc. Oral Solution, For the treatment of spinal muscular atrophy August 7, 2020 (risdiplam) 0.75 mg/mL (SMA) in patients 2 months of age and older. Viltepso NS Pharma, Inc. Injection, For the treatment of Duchenne muscular August 12, 2020 (viltolarsen) 50 mg/mL dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VILTEPSO. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
    [Show full text]
  • Severe Child Form of Primary Hyperoxaluria Type 2
    Konkoľová et al. BMC Medical Genetics (2017) 18:59 DOI 10.1186/s12881-017-0421-8 CASE REPORT Open Access Severe child form of primary hyperoxaluria type 2 - a case report revealing consequence of GRHPR deficiency on metabolism Jana Konkoľová1,2*, Ján Chandoga1,2, Juraj Kováčik3, Marcel Repiský2, Veronika Kramarová2, Ivana Paučinová3 and Daniel Böhmer1,2 Abstract Background: Primary hyperoxaluria type 2 is a rare monogenic disorder inherited in an autosomal recessive pattern. It results from the absence of the enzyme glyoxylate reductase/hydroxypyruvate reductase (GRHPR). As a consequence of deficient enzyme activity, excessive amounts of oxalate and L-glycerate are excreted in the urine, and are a source for the formation of calcium oxalate stones that result in recurrent nephrolithiasis and less frequently nephrocalcinosis. Case presentation: We report a case of a 10-month-old patient diagnosed with urolithiasis. Screening of inborn errors of metabolism, including the performance of GC/MS urine organic acid profiling and HPLC amino acid profiling, showed abnormalities, which suggested deficiency of GRHPR enzyme. Additional metabolic disturbances observed in the patient led us to seek other genetic determinants and the elucidation of these findings. Besides the elevated excretion of 3-OH-butyrate, adipic acid, which are typical marks of ketosis, other metabolites such as 3- aminoisobutyric acid, 3-hydroxyisobutyric acid, 3-hydroxypropionic acid and 2-ethyl-3-hydroxypropionic acids were observed in increased amounts in the urine. Direct sequencing of the GRHPR gene revealed novel mutation, described for the first time in this article c.454dup (p.Thr152Asnfs*39) in homozygous form. The frequent nucleotide variants were found in AGXT2 gene.
    [Show full text]
  • Rxoutlook® 4Th Quarter 2020
    ® RxOutlook 4th Quarter 2020 optum.com/optumrx a RxOutlook 4th Quarter 2020 While COVID-19 vaccines draw most attention, multiple “firsts” are expected from the pipeline in 1Q:2021 Great attention is being given to pipeline drugs that are being rapidly developed for the treatment or prevention of SARS- CoV-19 (COVID-19) infection, particularly two vaccines that are likely to receive emergency use authorization (EUA) from the Food and Drug Administration (FDA) in the near future. Earlier this year, FDA issued a Guidance for Industry that indicated the FDA expected any vaccine for COVID-19 to have at least 50% efficacy in preventing COVID-19. In November, two manufacturers, Pfizer and Moderna, released top-line results from interim analyses of their investigational COVID-19 vaccines. Pfizer stated their vaccine, BNT162b2 had demonstrated > 90% efficacy. Several days later, Moderna stated their vaccine, mRNA-1273, had demonstrated 94% efficacy. Many unknowns still exist, such as the durability of response, vaccine performance in vulnerable sub-populations, safety, and tolerability in the short and long term. Considering the first U.S. case of COVID-19 was detected less than 12 months ago, the fact that two vaccines have far exceeded the FDA’s guidance and are poised to earn EUA clearance, is remarkable. If the final data indicates a positive risk vs. benefit profile and supports final FDA clearance, there may be lessons from this accelerated development timeline that could be applied to the larger drug development pipeline in the future. Meanwhile, drug development in other areas continues. In this edition of RxOutlook, we highlight 12 key pipeline drugs with potential to launch by the end of the first quarter of 2021.
    [Show full text]
  • Place of Service for Medical Infusions “Notification” POLICY EFFECTIVE OCTOBER 1, 2021
    Corporate Medical Policy: Place of Service for Medical Infusions “Notification” POLICY EFFECTIVE OCTOBER 1, 2021 Related Corporate Medical Policies with Applicable Restricted Product(s): • Abatacept (Orencia®) • Alpha 1-Antitrypsin Inhibitor Therapy • Belimumab (Benlysta®) • Burosumab-twza (Crysvita®) • Canakinumab (Ilaris®) • Certolizumab pegol (Cimzia®) • Crizanlizumab-tmca (Adakveo®) • Eculizumab (Soliris®) • Edaravone (Radicava®) • Enzyme Replacement Therapy (ERT) for Lysosomal Storage Disorders • Eptinezumab-jjmr (Vyepti™) • Evinacumab-dgnb (Evkeeza™) • Fosdenopterin (Nulibry™) • Givosiran (Givlaari®) • Golimumab (Simponi Aria®) • Guselkumab (Tremfya®) • Ibalizumab-uiyk (Trogarzo®) • Immunoglobulin Therapy • Inebilizumab-cdon (Uplizna™) • Infliximab (Remicade®) and Infliximab Biosimilars • Interleukin-5 Antagonists • Letermovir (Prevymis™) • Lumasiran (Oxlumo™) • Luspatercept-aamt (Reblozyl®) • Natalizumab (Tysabri®) • Ocrelizumab (Ocrevus®) • Omalizumab (Xolair®) BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. Blue Cross NC is an independent licensee of the Blue Cross and Blue Shield Association. All other marks are the property of their respective owners. Page 1 October 2021 • Patisiran (Onpattro®) • Pegcetacoplan (Empaveli™) • Plasminogen, human-tvmh (Ryplazim®) • Ravulizumab-cwvz (Ultomiris®) • Romiplostim (NPlate®) • Romosozumab-aqqg (Evenity™) • Somatostatin Analogs • Teprotumumab-trbw
    [Show full text]
  • International Nonproprietary Names for Pharmaceutical Substances (INN)
    WHO Drug Information, Vol. 31, No. 2, 2017 Proposed INN: List 117 International Nonproprietary Names for Pharmaceutical Substances (INN) Notice is hereby given that, in accordance with article 3 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances, the names given in the list on the following pages are under consideration by the World Health Organization as Proposed International Nonproprietary Names. The inclusion of a name in the lists of Proposed International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy. Lists of Proposed (1–113) and Recommended (1–74) International Nonproprietary Names can be found in Cumulative List No. 16, 2015 (available in CD-ROM only). The statements indicating action and use are based largely on information supplied by the manufacturer. This information is merely meant to provide an indication of the potential use of new substances at the time they are accorded Proposed International Nonproprietary Names. WHO is not in a position either to uphold these statements or to comment on the efficacy of the action claimed. Because of their provisional nature, these descriptors will neither be revised nor included in the Cumulative Lists of INNs. Dénominations communes internationales des Substances pharmaceutiques (DCI) Il est notifié que, conformément aux dispositions de l'article 3 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques les dénominations ci-dessous sont mises à l'étude par l'Organisation mondiale de la Santé en tant que dénominations communes internationales proposées.
    [Show full text]